Matt O'Brien
Stock Analyst at Piper Sandler
(2.55)
# 2,113
Out of 4,670 analysts
171
Total ratings
50.71%
Success rate
-0.51%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Maintains: Overweight | $180 → $110 | $76.04 | +44.66% | 8 | Nov 20, 2024 | |
| PEN Penumbra | Maintains: Overweight | $235 → $250 | $244.84 | +2.11% | 12 | Nov 20, 2024 | |
| RCEL AVITA Medical | Reiterates: Neutral | $9 → $12 | $13.34 | -10.04% | 7 | Nov 8, 2024 | |
| SGHT Sight Sciences | Reiterates: Neutral | $6 → $5.5 | $4.01 | +37.16% | 6 | Nov 8, 2024 | |
| TELA TELA Bio | Maintains: Overweight | $8 → $5 | $3.01 | +66.11% | 5 | Nov 8, 2024 | |
| GMED Globus Medical | Maintains: Overweight | $80 → $100 | $84.72 | +18.04% | 11 | Nov 6, 2024 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $13 → $16 | $14.85 | +7.74% | 7 | Oct 30, 2024 | |
| SYK Stryker | Reiterates: Overweight | $380 → $420 | $384.85 | +9.13% | 12 | Oct 30, 2024 | |
| ITGR Integer Holdings | Reiterates: Overweight | $125 → $140 | $138.11 | +1.37% | 2 | Oct 25, 2024 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $75 | $93.60 | -19.87% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $285 | $262.93 | +8.39% | 7 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $72.83 | +23.58% | 10 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $86.21 | +4.40% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $1 | $0.32 | +215.86% | 12 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $10.04 | +19.52% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 → $55 | $30.81 | +78.51% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $12 | $10.06 | +19.28% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $140 | $144.00 | -2.78% | 8 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $74.91 | +6.79% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $40 | $35.74 | +11.94% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $205 → $245 | $191.71 | +27.80% | 4 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $40 | $26.68 | +49.93% | 6 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $12.56 | +99.04% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $40 | $26.34 | +51.86% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $4.49 | -33.18% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.45 | +211.42% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $62 | $90.00 | -31.11% | 2 | Jul 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $110.22 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $5.77 | +159.97% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $100.80 | +7.89% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $8.26 | +120.10% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $33.21 | +140.89% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.52 | +240.91% | 1 | Jun 24, 2020 |
TransMedics Group
Nov 20, 2024
Maintains: Overweight
Price Target: $180 → $110
Current: $76.04
Upside: +44.66%
Penumbra
Nov 20, 2024
Maintains: Overweight
Price Target: $235 → $250
Current: $244.84
Upside: +2.11%
AVITA Medical
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $13.34
Upside: -10.04%
Sight Sciences
Nov 8, 2024
Reiterates: Neutral
Price Target: $6 → $5.5
Current: $4.01
Upside: +37.16%
TELA Bio
Nov 8, 2024
Maintains: Overweight
Price Target: $8 → $5
Current: $3.01
Upside: +66.11%
Globus Medical
Nov 6, 2024
Maintains: Overweight
Price Target: $80 → $100
Current: $84.72
Upside: +18.04%
CVRx, Inc.
Oct 30, 2024
Reiterates: Overweight
Price Target: $13 → $16
Current: $14.85
Upside: +7.74%
Stryker
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $384.85
Upside: +9.13%
Integer Holdings
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $138.11
Upside: +1.37%
PROCEPT BioRobotics
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $93.60
Upside: -19.87%
Sep 17, 2024
Maintains: Overweight
Price Target: $230 → $285
Current: $262.93
Upside: +8.39%
Aug 26, 2024
Reiterates: Overweight
Price Target: $90
Current: $72.83
Upside: +23.58%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $86.21
Upside: +4.40%
Aug 9, 2024
Reiterates: Neutral
Price Target: $3 → $1
Current: $0.32
Upside: +215.86%
Aug 9, 2024
Reiterates: Overweight
Price Target: $15 → $12
Current: $10.04
Upside: +19.52%
Aug 2, 2024
Reiterates: Overweight
Price Target: $50 → $55
Current: $30.81
Upside: +78.51%
Aug 1, 2024
Maintains: Overweight
Price Target: $17 → $12
Current: $10.06
Upside: +19.28%
Aug 1, 2024
Maintains: Overweight
Price Target: $110 → $140
Current: $144.00
Upside: -2.78%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $74.91
Upside: +6.79%
Jul 31, 2024
Maintains: Overweight
Price Target: $65 → $40
Current: $35.74
Upside: +11.94%
Jul 1, 2024
Upgrades: Overweight
Price Target: $205 → $245
Current: $191.71
Upside: +27.80%
May 8, 2024
Maintains: Neutral
Price Target: $33 → $40
Current: $26.68
Upside: +49.93%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $12.56
Upside: +99.04%
Mar 27, 2024
Reiterates: Overweight
Price Target: $40
Current: $26.34
Upside: +51.86%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $4.49
Upside: -33.18%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.45
Upside: +211.42%
Jul 6, 2023
Maintains: Overweight
Price Target: $58 → $62
Current: $90.00
Upside: -31.11%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $110.22
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $5.77
Upside: +159.97%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $100.80
Upside: +7.89%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $8.26
Upside: +120.10%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $33.21
Upside: +140.89%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.52
Upside: +240.91%